TITLE

Health-Related Productivity Loss: NICE to Recognize Soon, Good to Discuss Now

AUTHOR(S)
Zhang, Wei; Anis, Aslam
PUB. DATE
May 2014
SOURCE
PharmacoEconomics;May2014, Vol. 32 Issue 5, p425
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The authors reflect on the decision of the Great Britain National Institute for Health and Care Excellence (NICE) of the social benefit of drugs, particularly health-related productivity loss. They emphasize the issues surrounding the measurement and valuation of productivity loss, including problems on double-counting, equity, and perspective. The lack of a gold standard or objective measures in presenteeism measurement is discussed.
ACCESSION #
95905513

 

Related Articles

  • UK NICE far from perfect, says health economist.  // PharmacoEconomics & Outcomes News;12/2/2006, Issue 517, p2 

    A reprint of the article "Economic Evaluation and Decision Making in the UK," by Martin J. Buxton in a 2006 issue of "PharmacoEconomics" is presented. It contends that there are significant problems in the decision-making process of Great Britain's National Institute for Health and Clinical...

  • Evaluation of genotyping methods and the relative cost of pharmacogenomics. DE MONACO, A.; BERRETTA, M.; PUGLIESE, S.; VALENTE, D.; CIAFFARAFA, S.; DI FRANCIA, R. // European Review for Medical & Pharmacological Sciences;Jul2014, Vol. 18 Issue 14, p2084 

    Recently, several methods to assess the quality of cost-effectiveness, cost-utility and cost-benefit in the pharmacogenomic field have become available. A relevant example is the National Institute for Health and Clinical Excellence (NICE). NICE forms a diverse clinical Advisory committee, which...

  • A stated preference binary choice experiment to explore NICE decision making. Tappenden, Paul; Brazier, John; Ratcliffe, Julie; Chilcott, James // PharmacoEconomics;2007, Vol. 25 Issue 8, p685 

    Objective: To explore whether the National Institute for Health and Clinical Excellence (NICE) takes account of concerns other than just incremental cost effectiveness in commissioning healthcare services.Method: A stated preference binary choice experiment was used to...

  • Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal. Greenhalgh, Janette; Bagust, Adrian; Boland, Angela; Oyee, James; Trevor, Nicola; Beale, Sophie; Dundar, Yenal; Hockenhull, Juliet; Proudlove, Chris; O'Reilly, Susan // PharmacoEconomics;Feb2015, Vol. 33 Issue 2, p137 

    The National Institute for Health and Care Excellence (NICE) invited the manufacturer of eribulin (Eisai Ltd) to submit evidence for the clinical and cost effectiveness of eribulin as treatment for patients with locally advanced or metastatic breast cancer (LABC/MBC) pre-treated with at least...

  • NICE says Inditherm blanket cost effective. McCarty, Mark // Medical Device Daily;9/1/2011, Vol. 15 Issue 167, p8 

    The article reports that the National Institutes of Health and Clinical Excellence (NICE) in Great Britain found the patient warming mattress of Inditherm to be cost effective.

  • NICE backs drug pricing scheme.  // GP: General Practitioner;4/1/2011, p7 

    The article offers information on the National Institute for Health and Clinical Excellence (NICE) of Great Britain and its support to drug pricing scheme. It states that NICE has backed the proposed value-based pricing scheme for National Health Service (NHS) drugs but warned that plans to...

  • Screening for hazardous alcohol consumption in a sexual health clinic: a service evaluation. Thorley, N.; Hettiarachchi, N.; Nightingale, P.; Radcliffe, K. // International Journal of STD & AIDS;Aug2012, Vol. 23 Issue 8, p585 

    On the basis of National Institute for Health and Clinical Excellence (NICE) guidance we conducted a survey in a sexual health clinic to assess acceptability of an alcohol screening questionnaire, rates of hazardous drinking and success of referral to a specialist alcohol service (Aquarius)....

  • NICE Forced to Disclose Economic Model. HOULTON, SARAH // Pharmaceutical Executive;Jun2008, Vol. 29 Issue 6, p34 

    The article focuses on the decision of the appeals court regarding the economic model of the National Institute for Health and Clinical Excellence (NICE) in Great Britain. The court ruled to disclose the full model used by the institute in determining the cost-effectiveness of the drugs for...

  • Criteria for deciding cost-effectiveness for expensive new anti-cancer agents. Sarin, Rajiv // Journal of Cancer Research & Therapeutics;Mar2008, Vol. 4 Issue 1, p1 

    The article focuses on the use of incremental cost-effectiveness ratio (ICER) in assessing expensive anti-cancer agents, according to the National Institute for Health and Clinical Excellence (NICE) in Great Britain. It mentions that targeted therapies offer new hope for cancer patients and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics